Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients

@inproceedings{Estve2017EfficacyAS,
  title={Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients},
  author={Cl{\'e}mentine Est{\`e}ve and Maxime Samson and Alexandre Guilhem and Barbara Nicolas and Vanessa Leguy-Seguin and Sylvie Berthier and Bernard Bonnotte and Sylvain Audia},
  booktitle={PloS one},
  year={2017}
}
Dapsone is recommended as a second line therapy in immune thrombocytopenia (ITP), but is underused because of its potential side effects. The medical charts of 42 ITP patients treated with dapsone (100 mg/day) were retrospectively reviewed in order to assess its efficacy and safety in daily clinical practice. The overall response rate was 54.8% (n = 22, with a complete response in 38.1%) with a median time to response of 29 days (24-41 days). Patients with complete response had shorter disease… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Hydroxychloro - quine is a good second - line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies

F Maloisel, E Andres, +3 authors A Koumarianou
  • Am J Hematol
  • 2014

Safety and efficacy of rituximab in adult immune thrombocytopenia : results from a prospective registry including 248 patients

M Khellaf, A Chabrol, +3 authors L Lanquille
  • Blood
  • 2014